NEW YORK (GenomeWeb) – Illumina today announced agreements with three organizations for use of its next-generation sequencing technologies to develop and run non-invasive prenatal testing in parts of Europe.

Illumina's deals are with Biomnis, which plans to make NIPT available in France; with Genoma for NIPT services in Italy; and with the Center for Human Genetics and Laboratory Diagnostics, which will offer NIPT in Germany.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.